Antihypertensive peptide derived from highland barley protein

By using machine learning and peptidomics technologies to screen and identify antihypertensive peptides from barley protein, the problem of high-throughput screening and unclear multi-target mechanisms in the study of hydrolyzed barley protein peptides has been solved, achieving efficient screening and commercial production of significant ACE-inhibiting peptides.

CN118994304APending Publication Date: 2024-11-22CHINA AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411000855.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the existing technology, the research on the ACE inhibitory effect of barley protein hydrolysate peptides is limited, high-throughput screening technology is lacking, traditional separation and purification methods lead to the omission of effective antihypertensive peptides, and the multi-target mechanism behind their antihypertensive properties is not well understood.

Method used

Using machine learning models combined with peptidomics technology, antihypertensive peptides were screened and identified from barley protein. The peptide sequences were identified by enzymatic digestion and ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Peptides with high ACE inhibitory activity were screened by combining molecular docking and molecular dynamics simulation.

Benefits of technology

This method enables efficient screening of peptides with significant ACE inhibitory effects from barley protein, reducing the cost and time required to discover bioactive peptides, simplifying the discovery process of ACE-inhibiting peptides, and has practical application value, thus promoting the large-scale production and commercialization of food-derived bioactive peptides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994304A_ABST
    Figure CN118994304A_ABST
Patent Text Reader

Abstract

The invention provides a highland barley protein-derived antihypertensive peptide. The amino acid sequence of the highland barley protein-derived antihypertensive peptide is one or more of 1-10 sequences. The invention also provides a method for screening and identifying antihypertensive peptides from highland barley proteins through machine learning. The method comprises the following steps: S1, constructing a database; s2, training a machine learning model; s3, model evaluation; s4, preparing highland barley defatted powder and HBP; s5, preparing an HBP hydrolysate; s6, determining the inhibitory activity of angiotensin converting enzyme; s7, identifying a peptide sequence through ultra-high performance liquid chromatography-tandem mass spectrometry; computer prediction of the S8 peptide sequence and determination of the IC50 value of the candidate peptide. The research strategy provided by the method not only simplifies the discovery process of the ACE inhibitory peptide and makes the ACE inhibitory peptide become an economical and efficient prediction pipeline, but also has practical application value, is beneficial to large-scale production and preparation of the food-sourced bioactive peptide, and promotes commercial production of the food-sourced bioactive peptide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of polypeptides, and particularly relates to a method for identifying peptides from highland barley protein. Background Art

[0002] Hypertension is defined as persistently elevated vascular pressure (≥140 / 90 mmHg). Elevated blood pressure is primarily regulated by the renin-angiotensin-aldosterone system (RAAS)[1]. Angiotensin I converting enzyme (ACE) plays a role by regulating the balance of the renin-angiotensin system. ACE is a specific metallopeptidase that catalyzes the conversion of angiotensin I to angiotensin II. [2] The production of angiotensin II promotes the synthesis and release of aldosterone, which further causes vasoconstriction and increases blood pressure. [3] . Therefore, substances that effectively inhibit ACE may help relieve hypertension. Although a variety of ACE inhibitors have been developed, such as captopril, lisinopril, ramipril and enalapril, these synthetic drugs may have adverse effects on human health, including headaches, asthma and reversible renal dysfunction. Therefore, it is particularly important to explore the potential of natural, safe, healthy and economical antihypertensive drugs. Previous studies have found that many food-derived substances contain antihypertensive active ingredients, including peptides, polyphenols and polysaccharides. The high yield, diversity and lack of side effects of antihypertensive peptides make them an increasingly important research focus.

[0003] Plateau barley (HB, Hordeum vulgare L. var. nudum Hook. F.), also known as highland barley, is a unique cereal in China that is widely grown in the Qinghai-Tibet Plateau region of western China. Compared with traditional cereals such as sorghum, wheat, and rice, HB is known for its high content of protein, β-glucan, flavonoids, vitamins, trace elements (zinc and selenium), and dietary fiber. Studies have shown that active peptides in HB wine have ACE inhibitory activity [4]. However, research on the ACE inhibitory effect of HB hydrolyzed peptides is still limited and needs further exploration. In addition, grain-related peptide research faces many challenges, including the lack of high-throughput screening technology to accurately identify antihypertensive peptides, the limitations of traditional separation and purification methods that lead to the omission of effective antihypertensive peptides, insufficient exploration of the binding interactions between identified antihypertensive peptides and ACE, and a vague understanding of the multi-target mechanisms behind their antihypertensive properties. Machine learning can analyze large amounts of data and select the most appropriate algorithm for accurate prediction. This advantage makes it possible to conduct high-throughput evaluation of the antihypertensive properties of peptides, thereby narrowing the scope of experimental verification.

[0004] References

[0005] [1]te Riet L, van Esch JHM, Roks AJM, van den Meiracker AH, Danser AHJ. Hypertension. Circulation Research 2015;116:960–75. https: / / doi.org / 10.1161 / CIRCRESAHA.116.303587.

[0006] [2]Lee JH, Kim T-K, Yong HI, Cha JY, Song K-M, Lee HG, et al. Peptides inhibiting angiotensin-I-converting enzyme: Isolation from flavourzyme hydrolysate of Protaetia brevitarsis larva protein and identification. Food Chemistry 2023;399:133897. https: / / doi.org / 10.1016 / j.foodchem.2022.133897.

[0007] [3]Rosendorff C. The Renin-Angiotensin System and Vascular Hypertrophy. Journal of the American College of Cardiology 1996;28:803–12. https: / / doi.org / 10.1016 / S0735-1097(96)00251-3.

[0008] [4]Yin Z, Yan R, Jiang Y, Feng S, Sun H, Sun J, et al. Identification of peptides in Qingke baijiu and evaluation of its angiotensin converting enzyme (ACE) inhibitory activity and stability. Food Chemistry 2022;395:133551. https: / / doi.org / 10.1016 / j.foodchem.2022.133551. Summary of the Invention

[0009] In view of the shortcomings of the prior art, the present invention provides a blood pressure lowering peptide derived from highland barley protein.

[0010] The second objective of the present invention is to propose a method for extracting and identifying antihypertensive peptides from highland barley, obtaining highland barley protein by enzymatic hydrolysis, screening and identifying antihypertensive peptides from highland barley protein by machine learning, and combining peptideomics with machine learning technology to identify antihypertensive peptides from HB protein.

[0011] The technical solution for achieving the above-mentioned purpose of the present invention is:

[0012] A highland barley protein-derived antihypertensive peptide, wherein the amino acid sequence of the highland barley protein-derived antihypertensive peptide is one or more of the following sequences:

[0013] FPRPF, PESFF, APFFS, FPRPFL, PLLFP, EPFLPF, RAPFF, EFFPIG, APFFSL, LPFPQ,

[0014] The antihypertensive peptide is extracted from highland barley.

[0015] A method for extracting and identifying antihypertensive peptides from highland barley comprises the following steps:

[0016] S1 Database construction: Use public peptide databases to collect non-repetitive experimentally validated antihypertensive peptides;

[0017] S2 Machine Learning Model Training: Using a machine learning model to predict protein-peptide activity; the machine learning model is GBDT (gradient boosted decision tree), and the specific data set collected in S1 is used to train the machine learning model; the features used in the feature representation of the machine learning model include PseAAC (pseudo amino acid composition), and PseAAC uses "Type 2";

[0018] S3 model evaluation: In the evaluation stage, the model is trained using a five-fold cross-validation method, and five key performance indicators are used to quantitatively evaluate the predictive ability of the model. The key performance indicators are accuracy, recall, precision, F1 score, and ROC curve.

[0019] S4 Preparation of defatted highland barley powder and highland barley protein (HBP): After grinding highland barley, mixing with an organic solvent, and drying to obtain defatted highland barley powder; the organic solvent is one or more of n-hexane, butane, ethylene glycol, petroleum ether, and ethyl acetate;

[0020] The defatted highland barley powder is mixed with water, the pH value is adjusted to 10-12, the mixture is heated at 50-70°C and then centrifuged to collect the supernatant; the pH value of the supernatant is adjusted to 4-5, the mixture is centrifuged and the supernatant is discarded; the obtained crude extract is dialyzed, the dialyzate is centrifuged, and the purified HBP is precipitated;

[0021] S5 Preparation of HBP hydrolysate: using one or more of alkaline protease, pepsin, trypsin and papain to hydrolyze HBP, the hydrolysis pH is 2.0 to 8.0, the temperature is 35 to 65°C, and the hydrolysis time is 5 to 8 hours;

[0022] S6: Determination of angiotensin converting enzyme inhibitory activity: Determine the ACE inhibitory activity of the product obtained in step S5, and select the molecular weight range of the peptide segment with higher ACE inhibitory activity;

[0023] S7 identified peptide sequences by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS);

[0024] Computer prediction of S8 peptide sequences and candidate peptide IC 50 Determination of value: The sequencing results of the peptides in step S7 are applied to the GBDT model to predict ACE inhibitory activity. Computational virtual screening of bioactive peptides is a fast and effective method to verify the biological activity of each peptide.

[0025] Optionally, in step S2, the weight factor of the amino acid correlation in the description is set to 0.05.

[0026] The lambda value is set to 1.

[0027] In this study, the “Type 2” description was adopted because it can highlight the interoperability of consecutive amino acids. The λ value was set to 1 to take into account the proximity of amino acids. In addition, the pKa values ​​and isoelectric points of the α-carboxyl and amino groups at 25 °C were used to evaluate the physicochemical properties of amino acids.

[0028] In step S3, Accuracy is a direct measure of the model's ability to correctly predict all samples. Recall is the proportion of actual positive samples that the model correctly identifies as positive. Precision (Prec) is defined as the percentage of actual positive cases among samples predicted as positive by the model. The F1 score (F1) is the harmonic mean of precision and recall, and is used as a single indicator of the overall performance of the model. The ROC curve shows the trade-off between the true positive rate and the false positive rate of the model at different thresholds. AUC (area under the ROC curve) provides a quantifiable measure of the likelihood that the model will rank randomly selected positive examples higher than negative examples. By integrating these metrics, we can comprehensively evaluate and compare the performance of the models.

[0029] Preferably, in step S3, the data collected in step S1 is divided into five subsets, four of which are used for training and the remaining subset is used for testing. This process is repeated five times, and a different test set is selected in each iteration to ensure that every data point is tested. The model is trained using batch gradient descent, and the optimal setting is determined by grid search optimization.

[0030] Wherein, in step S4, highland barley defatted powder and water are mixed in a mass ratio of 1:20-30, and the pH value of the solution is adjusted to 11, and then the mixture is heated at 55-65° C. for 25-35 minutes, and then centrifuged at a speed of 5000-10000 rpm for 10-15 minutes, and the supernatant is collected; the pH value of the liquid is adjusted to 4.5, and the mixture is centrifuged again at a speed of 5000-10000 rpm for 15-30 minutes, the supernatant is discarded, and the crude extract is precipitated; this process is repeated 2-4 times to ensure that the protein is completely purified.

[0031] In step S4, the crude extract is then mixed with distilled water to form a suspension, which is dialyzed for 20 to 30 hours; finally, the dialyzate is centrifuged at 5000 to 10000 rpm for 10 to 30 minutes to precipitate purified HBP. The pore size of the dialysis bag can be 5 to 10 kDa.

[0032] More preferably, in step S5, HBP is hydrolyzed using papain at a pH of 6 to 7, a temperature of 58 to 62° C., and a hydrolysis time of 5 to 7 hours. ; and / or

[0033] The hydrolyzate was further separated: the hydrolyzate was centrifuged in an ultrafiltration centrifuge tube, the hydrolyzate was first filtered through a 10 kDa filter membrane, and then the solution obtained by passing through the 10 kDa filter membrane was filtered through a 3 kDa ultrafiltration membrane to obtain three separate products with different molecular weight ranges, that is, three separate products with different molecular weight ranges: <3 kDa, 3-10 kDa and >10 kDa.

[0034] One of the preferred technical solutions of the present invention is that in step S7, the isolates with a molecular weight range of <3 kDa are selected to identify the peptide sequence using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS).

[0035] A further preferred technical solution of the present invention is that in step S8, first a preliminary screening is performed: screening is performed by combining the denovo score, peptide activity ranking and GBDT prediction score to obtain candidate peptides; then a second round of screening is performed: the evaluation index of the second round of screening is to select peptides with a peptide length between 3-8 amino acids; the third round of screening: molecular docking is used as the screening procedure, and binding energy is used as a measure of the interaction strength.

[0036] Molecular docking was used as a screening procedure to simulate the interaction between ACE inhibitory peptides and ACE. Binding energy, as a measure of the strength of the interaction, provided insights into the binding affinity of the peptide to the protein.

[0037] More preferably, in step S9, in step S9, candidate peptides are obtained by selecting peptides with a denovo score greater than 90%, a GBDT prediction score greater than 50, and a peptide activity ranking score greater than 0.8; second round of screening: the evaluation index of the second round of screening is to select peptides with a peptide length between 3-8 amino acids, and delete peptide sequences of unknown origin; third round of screening: peptides with a binding energy ≤-8.0 kcal / mol and a comprehensive score ranking in the top 10 are identified,

[0038] In the second round of screening, the evaluation criteria were to select peptides with a length of 3-8 amino acids, and to ensure that the protein information of these hydrolyzed peptide sequences could be found on Uniprot, and to delete peptide sequences of unknown origin.

[0039] Another preferred technical solution proposed by the present invention is to artificially synthesize the peptide of the sequence predicted in step S8. Test the physicochemical properties and half inhibitory concentration (IC 50 ) value; preferably select the peptide synthesis with the lowest half inhibitory concentration to study its biochemical properties.

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] The highland barley protein-derived antihypertensive peptide proposed in the present invention is, as far as we know, the first antihypertensive peptide mined from highland barley (HB), and the antihypertensive peptide showed a highly effective ACE inhibitory effect. In our study, the IC 50 The values ​​were 1.18 μM and 23.12 μM, respectively, which indicated that they had significantly better ACE inhibitory effects than most ACE inhibitory peptides discovered so far.

[0042] The present invention uses machine learning to screen and identify antihypertensive peptides from highland barley protein, and uses a variety of enzymatic hydrolysis methods to determine the optimal enzymatic hydrolysis conditions for highland barley protein raw materials; through peptidomics technology, peptide information is obtained from the hydrolyzate that shows the most significant inhibitory effect. Machine learning methods are used to perform comprehensive high-throughput screening of potential antihypertensive peptides. Subsequently, computational analysis and molecular docking are used to further screen peptides and evaluate the IC values ​​of peptides that show the strongest ACE inhibitory activity. 50 , inhibition mode and stability The method proposed in this application will help to systematically study ACE peptides from food sources. This innovative method not only reduces the cost and time required to discover bioactive peptides, but also comprehensively evaluates the functions of ACE inhibitory peptides.

[0043] By studying the identified antihypertensive peptides using molecular docking, molecular dynamics simulation and network pharmacology, a strategy for rapid screening and mining of ACE inhibitory peptides was established.

[0044] This extraction and identification method not only simplifies the discovery process of ACE inhibitory peptides, making it a cost-effective prediction pipeline, but also has practical application value, which is conducive to the large-scale production and preparation of food-derived bioactive peptides and promotes their commercial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 : Experimental flow chart for extracting and identifying ACE inhibitory peptides from highland barley.

[0046] Figure 2 : Machine learning model results. (a) Evaluation indicators of machine learning models. The results show the average value of each indicator, where Accuracy, Recall, Prec and F1 represent accuracy, recall, precision and F1 score respectively. (b) ROC curve and AUC value of CatBoost. (c) ROC curve and AUC value of GBDT; (d) ROC curve and AUC value of LightGBM; (e) ROC curve and AUC value of XGBoost. ROC: model operating characteristic curve, AUC: area under the ROC curve.

[0047] Figure 3 : Results of ACE inhibitory activity of different components and peptide prediction results. (f) ACE inhibitory activity of HBP under four enzymatic hydrolysis conditions. (g) ACE inhibitory activity of HBP-pap and three components separated in different molecular weight ranges (<3k Da, 3-10k Da, >10k Da). (h) Histogram of predicted peptide scores. (i) Amino acid distribution under different prediction scores. A = Alanine (Ala); R = Arginine (Arg); N = Asparagine (ASN); D = Aspartic acid (Asp); C = Cysteine ​​(Cysteine, Cys); Q = Glutamine (Gln); E = Glutamic acid (Glu); G = Glycine (Gly); I = Isoleucine (Ile); L = Leucine (Leu); K = Lysine (Lys); M = Methionine (Met); F = Phenylalanine (Phe); P = Proline (Pro); S = Serine (SER); T = Threonine (THR); W = Tryptophan (TRP); Y = Tyrosine (Tyr); V = Valine (Val). Error bars represent mean ± standard deviation. Different letters a, b, c, d represent significant differences when P < 0.05.

[0048] Figure 4 The results of in vitro experiments. (a) IC of peptide APFFS 50curve; (b) IC of peptide FPRPF 50 Curve; (c) IC of peptide FPRPFL 50 Curve; (d) IC of peptide PESFF 50 Curve. Logarithmic concentrations 1, 0, -1, -2 correspond to 10, 1, 0.1, 0.01 (mg / mL), respectively. (e) Docking posture of APFFS (purple) at the active site of human ACE; (f) Docking posture of FPRPF (orange) at the active site of human ACE; (g) Docking posture of FPRPFL (blue) at the active site of human ACE; (h) Docking conformation of PESFF at the active site of human ACE (color), protein is represented by cartoon, docked peptide is represented by stick, zinc ion and chloride ion are represented by yellow and green spheres, respectively. (i) CD spectrum of ACE with FPRPFL; (j) ACE secondary structure content of FPRPFL. (k) ACE inhibition Lineweaver-Burk plot of FPRPFL. (l) In vitro simulated digestion stability of FPRPFL.

[0049] Figure 5 The molecular docking results. (a) Global schematic diagram and (b) local schematic diagram of the FPRPFL-ACE system. Dynamic simulation results of the FPRPFL-ACE system (c) Overall structure diagram and (d) Local binding detail diagram. (e) Two-dimensional interaction diagram of the FPRPFL-ACE system. (f) Two-dimensional interaction diagram of the stable structure of the FPRPFL-ACE system after dynamic simulation. In the figure. (a)-(d), hydrogen bonds are represented by red dot lines, salt bridges are represented by blue dot lines, green ions are π, and purple π-π. The protein is represented by Cartoon and solvent, the pocket domain is represented by a ball model, and the polypeptide and surrounding amino acids are represented by a stick model. In Figures (e)-(f), hydrogen bonds are represented by green dotted lines, red dotted lines represent salt bridges, and eyelashes represent van der Waals bases.

[0050] Figure 6 Molecular dynamics simulation of FPRPFL-ACE complex. (a) Root mean square deviation (RMSD) of FPRPFL and ACE changes with time, (b) root mean square fluctuation (RMSF) changes with time, gyration radius (c) value and hydrogen bond number (d) changes with time. Red represents ACE, blue represents FPRPFL, and black represents FPRPFL-ACE system. DETAILED DESCRIPTION

[0051] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0052] In the test, the angiotensin converting enzyme inhibitory activity was determined as follows: 15 μL of sample (10 mg / mL) was taken and pre-incubated with 10 μL of ACE solution (100 mU / mL; Sigma-Aldrich Co.) at 37°C for 10 minutes. Subsequently, the mixture was incubated at 37°C with 50 μL of HHL solution containing 5 mM hippurylhistidylleucine (HHL), 100 mM sodium borate buffer (pH 8.3) and 300 mM NaCl for 60 minutes, followed by the addition of 75 μL of 1 M HCl. Subsequently, 150 μL of chemically pure pyridine (Tianjin Chemical Reagent Company) was added, followed by the addition of 75 μL of benzenesulfonyl chloride (Shanghai Mike Biotechnology Co., Ltd.). The solution was vortexed for one minute and immediately placed in an ice bath to cool. Subsequently, 200 μL was transferred to a 96-well plate and the absorbance was measured at a wavelength of 410 nm. The angiotensin converting enzyme inhibitory activity was calculated according to formula (1):

[0053]

[0054] A represents the absorbance of the sample, B represents the absorbance of the control, and C represents the absorbance of the blank.

[0055] In the embodiment, the peptide was synthesized by the amino acid synthesis method protected by fluorenylmethoxycarbonyl chloride, and the purity of the synthesized peptide was above 95% as detected by high performance liquid chromatography.

[0056] Unless otherwise specified, the test materials and testing instruments used in the instructions can be purchased commercially.

[0057] Embodiment 1:

[0058] This embodiment provides a method for extracting and identifying antihypertensive peptides from highland barley, comprising the steps of:

[0059] S1 Database construction: Use public peptide databases to collect non-repetitive experimentally verified antihypertensive peptides; this example uses the following five public peptide databases: BIOPEP-UWM (https: / / biochemia.uwm.edu.pl / ), FermFooDB (https: / / webs.iiitd.edu.in / raghava / fermfoodb / ), PlantPepDB (http: / / www.nipgr.ac.in / PlantPepDB / ), MBPDB (http: / / mbpdb.nws.oregonstate.edu), and DFBP (http: / / www.cqudfbp.net / ). A total of 1,687 non-repetitive, experimentally verified antihypertensive peptides were collected.

[0060] S2 Machine Learning Model Training: Four machine learning models were used: CatBoost, GBDT, LightGBM and XGBoost to predict protein-peptide activity;

[0061] Among them, PseAAC adopts "Type 2"; it is used to enhance the interpretability of protein sequences. The weight factor of amino acid correlation in the description is set to 0.05. The λ value is set to 1 to consider the adjacency of amino acids. In addition, the pKa values ​​and isoelectric points of α-carboxyl and amino groups at 25°C are used to evaluate the physicochemical properties of amino acids.

[0062] S3 Model Evaluation: In the evaluation phase, the model is trained using a five-fold cross-validation method, and five key performance indicators are used to quantitatively evaluate the model's predictive ability, including ROC curve, accuracy, recall, precision, and F1 score. The calculation formula is as follows.

[0063]

[0064]

[0065] Where TN is the number of true negatives, TP is the number of true positives, FN is the number of false negatives, and FP is the number of false positives.

[0066] The model was trained by performing a 5-fold cross-validation method on the specific dataset collected in S1 to achieve optimal performance in peptide activity prediction.

[0067] The results are as follows Figure 2 (a) to (e). The GBDT model showed excellent classification ability, and its AUC value was higher than that of the other four models, which was confirmed by five-fold cross validation. In addition, the accuracy of the GBDT model was 84.07, which was better than the other three models. Its accuracy and F1 value were 85.14 and 85.40, respectively, both exceeding the CatBoost model. This shows that the model has excellent generalization ability and stability. However, the recall rate of the GBDT model was lower than that of the other models (p<0.05). In summary, the performance of the GBDT model was better than that of the other four models, so it was selected as the screening model for ACE inhibitory peptides.

[0068] Example 2

[0069] This embodiment provides a method for extracting and identifying antihypertensive peptides from highland barley, wherein steps S1 and S3 are the same as those in embodiment 1;

[0070] S2 Machine Learning Model Training: The machine learning model used is GBDT (gradient boosted decision tree) to predict protein-peptide activity; the operation and model evaluation of the machine learning model are the same as in Example 1;

[0071] The data collected in step S1 is divided into five subsets, four of which are used for training and the remaining one is used for testing. This process is repeated five times, and a different test set is selected in each iteration to ensure that every data point is tested. The model is trained using batch gradient descent, and the optimal settings are determined by grid search optimization.

[0072] Preparation of S4 defatted highland barley powder and highland barley protein (HBP): After washing highland barley (HB) of Tibetan blue 320 variety, it was ground and screened with a 60-mesh sieve to obtain HB powder. The HB powder was mixed with n-hexane in a ratio of 1:5 and stirred at 37°C for 4 hours. After being placed in a fume hood for 12 hours, the liquid was discarded and the remaining solid was volatilized for 12 hours to obtain HB defatted powder.

[0073] HB defatted powder was mixed with water in a mass ratio of 1:25, and the pH value of the solution was adjusted to 11. Subsequently, the mixture was heated in a 60°C water bath for 30 minutes, then centrifuged at 8000 rpm for 10 minutes, and the supernatant was collected. The pH value of the liquid was adjusted to 4.5, centrifuged again at 8000 rpm for 20 minutes, and the supernatant was discarded. This process was repeated three times to ensure complete purification of the protein. The crude HBP extract was then mixed with distilled water to form a suspension and dialyzed for 24 hours (dialysis bag pore size 8 kDa). Finally, the dialysate was centrifuged at 8000 rpm for 20 minutes to precipitate purified HBP.

[0074] HBP was freeze-dried in a freeze dryer at -42 °C for 48 h and then stored at -20 °C. The nitrogen content of HBP was determined using the Kjeldahl method: 0.50 g of HBP was digested in 10 ml of sulfuric acid for 150 min and then measured using a Kjeldahl apparatus. The protein content was calculated based on the nitrogen content with a conversion factor of 5.83. This was repeated three times.

[0075] Preparation of S5 HBP hydrolysate: HBP was hydrolyzed using alkaline protease (Beijing Sol Biotechnology Co., Ltd.), pepsin (Beijing Bosi Biotechnology Co., Ltd.), trypsin (Beijing Bosi Biotechnology Co., Ltd.) and papain (Shanghai Titan Technology Co., Ltd.), respectively.

[0076] HBP powder was dissolved in pure water at a concentration of 10 mg / mL. Subsequently, the samples were hydrolyzed with alkaline protease at pH = 8.0 and 60°C for 6 hours, with pepsin at pH = 2.0 and 37°C for 6 hours, with trypsin at pH = 7.5 and 41°C for 6 hours, and with papain at pH = 6.5 and 60°C for 6 hours. Then, the samples were heated at 121°C for 10 minutes. The hydrolyzate was further separated: first, it was centrifuged at 8,000 rpm for 60 minutes in a 10 kDa ultrafiltration centrifuge tube, and then the centrifuged solution was centrifuged at 8,000 rpm for 60 minutes in a 3 kDa ultrafiltration centrifuge tube to obtain three separate products with different molecular weight ranges: <3 kDa, 3-10 kDa, and >10 kDa.

[0077] S6 Determination of angiotensin converting enzyme inhibitory activity: Determine the ACE inhibitory activity of the product purified in step S6, and select the molecular weight range of the peptide segment with higher ACE inhibitory activity;

[0078] The protein content of purified HBP was 90.24±0.17%. HBP was hydrolyzed by four enzymes to produce four components: Alcalase (alkaline protease product), Pepsin (pepsin product), Trypsin (trypsin product) and Papain (papain product). The ACE inhibitory activity of the four enzymatic peptides was quantified. The results are as follows: Figure 3 (f) As shown in Figure 2, papain (80.41±0.63%) had the highest ACE inhibition rate, followed by trypsin (75.89±0.68%), pepsin (71.37±0.63%), and alkaline protease (64.84±1.42%). This suggests that papain hydrolysis of HB protein may lead to the production of peptides with greater ACE inhibitory activity.

[0079] The papain hydrolysate of HBP was separated into three fractions (<3k Da, 3-10kDa, >10k Da) and their ACE inhibitory activities were analyzed. Figure 3 As shown in (g), the component with a molecular weight <3 kDa showed the highest ACE inhibitory activity (83.78±0.21%), followed by Papain (80.41±0.63%), the component with a molecular weight between 3 kDa and 10 kDa (67.76±0.22%), and the component with a molecular weight greater than 10 kDa (53.07±0.68%) ( Figure 3In (g), papain refers to the total fraction of papain without ultrafiltration. This result indicates that low molecular weight (MW < 3 kDa) peptides generally have higher ACE inhibitory activity, which may be due to the fact that low molecular weight peptides are more likely to bind to the active site of ACE than high molecular weight peptides. Moreover, small molecular weight peptides are more easily absorbed by the human body, enabling them to exert their antihypertensive effect.

[0080] Example 3

[0081] This example provides a method for extracting and identifying antihypertensive peptides from highland barley. The extraction and identification process is shown in Figure 1 , wherein steps S1 to S4 and S6 are the same as those in Example 1,

[0082] S5 HBP hydrolysate was prepared by enzymatic hydrolysis with papain, and the operation was the same as in Example 2;

[0083] S7 Identification of peptide sequences by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS):

[0084] The peptide mixture (the fraction with molecular weight <3 kDa, referred to as the peptide mixture because the separation contained many peptides) was desalted using Pierce C18 Spin Tips. The peptides were redissolved in solvent A (0.1% formic acid in water) and analyzed using an Orbitrap Fusion Lumos coupled to an EASY-nanoLC 1200 system (Thermo Fisher Scientific, MA, USA). Two microliters of the peptide sample were loaded onto a 25 cm analytical column (75 μm inner diameter, 1.9 μm resin (Dr. Maisch)) and separated using a 60-min gradient. The gradient started with 4% buffer B (containing 80% acetonitrile and 0.1% FA), increased stepwise to 50% in 53.6 min, increased to 90% in 40 s, and maintained at that level for 5.6 min. The column flow rate was maintained at 300 nL / min, and the column temperature was set to 40 °C. The electrospray voltage was set to 2 kV. The mass spectrometer was operated in data-dependent acquisition (DDA) mode, automatically switching between MS and MS / MS modes. A full scan in the Orbitrap was acquired in full-scan MS spectra (m / z: 350–1500) with a resolution of 120,000. The normalized automatic gain control (AGC) target was set to 200% and the maximum injection time was fixed to 50 ms. Subsequently, the selected precursor ions were fragmented in the collision cell by high-energy collision dissociation (HCD) with collection energies of 25%, 30%, and 35%. The MS / MS resolution was set to 15,000, the normalized AGC target was set to 100%, the maximum injection time was set to 25 ms, and the dynamic exclusion was set to 30 s.

[0085] Computer prediction of S8 peptide sequences and candidate peptide IC50 Determination of value:

[0086] The UPLC-MS / MS sequencing results of the peptides were applied to the GBDT model to predict ACE inhibitory activity. The distribution of different scores is shown in Figure 2. Figure 3 The distribution of amino acids in peptides with ACE prediction scores greater than 70 and less than 10 was analyzed, as shown in (h). Figure 3 (i) It was observed that the proportion of hydrophobic amino acids (such as Gly (G), Leu (L), Ile (I), Pro (P), Phe (F) and Val (V)) was higher in peptides with HB prediction scores of more than 70. This suggests that the presence of certain hydrophobic amino acids may enhance the ACE inhibitory activity of the peptides. In peptides with ACE prediction scores less than 10, the proportions of amino acids such as Cys (C), Lys (K), Gln (Q), Thr (T) and Try (W) were higher, indicating that these amino acids did not contribute to ACE inhibition.

[0087] A total of 63,301 peptides were generated from the fragments identified by UPLC-MS / MS of HBP papain hydrolysate (MW < 3 kDa). In the preliminary screening, 1,259 non-repetitive peptides were obtained by selecting peptides with a denovo score greater than 90%, a GBDT prediction score greater than 50, and a PeptideRanker score greater than 0.8. In order to make the screening range more precise, 1,259 peptides are still relatively large and need to be further screened before molecular docking is performed to calculate the docking energy. Second round of screening: Peptides with a length of less than eight amino acids were used to determine the protein source, and the protein information of these peptide sequences that can be hydrolyzed was ensured to be found on Uniprot, and peptide sequences of unknown origin were deleted; 160 peptides were finally selected. Third round of screening: Molecular docking was used as a screening procedure to simulate the interaction between ACE inhibitory peptides and ACE; binding energy was used as a measure of the strength of the interaction. Therefore, peptides with binding energy ≤-8.0 kcal / mol and the top 10 comprehensive scores were identified, as shown in Table 1. The binding energies of APFFS, FPRPF, FPRPFL and PESFF were -9.3 kcal / mol, -8.7 kcal / mol, -8.9 kcal / mol and -8.5 kcal / mol, respectively, indicating that these four peptides can bind tightly to ACE. The overall binding positions of APFFS, FPRPF, FPRPFL and PESFF to ACE were depicted by PyMOL, as shown in Figure 4 As shown in (e) to (h).

[0088] Table 1: Results of machine learning prediction and molecular docking

[0089]

[0090]

[0091] Example 4

[0092] In order to verify the performance of the hypotensive peptides proposed in the present invention, some of the peptides in Table 1 were synthesized for subsequent in vitro experiments. Considering the cost issue, four of the peptides identified in Example 3 (Table 1) were synthesized using the amino acid synthesis method protected by fluorenylmethoxycarbonyl chloride, and the physicochemical properties and IC of the synthesized peptides were tested. 50 value.

[0093] In computer simulation, four potential highly active ACE inhibitory peptides were identified by virtual screening technology, and the physicochemical properties of these four synthetic peptides are listed in Table 2. All four peptides exhibited non-toxic properties and showed effective intestinal absorption, with steric hindrance values ​​ranging from 0.56 to 0.59. The GRAVY values ​​of FPRPFL and APFFS were both negative, indicating good hydrophobicity.

[0094] Table 2: Physicochemical properties and IC of synthetic peptides 50 value

[0095]

[0096]

[0097] PI refers to isoelectric point, which is predicted using the Pepdraw tool; the GRAVY index is the overall average of the hydrophilicity (the sum of the hydrophilicity values ​​of all amino acids, divided by the number of residues in the sequence) predicted by the Protparam tool. The positive and negative values ​​of the GRAVY index represent the hydrophobicity and hydrophilicity of the peptide, respectively. HIA (human intestinal absorption) is predicted using the admetSAR tool. Toxicity and steric hindrance are predicted using the ToxinPred tool. IC 50 The value refers to the sample concentration required to inhibit ACE activity by 50% under the assay conditions.

[0098] Calculation of the biological activity of peptides: The biological activity of the identified peptides was evaluated using PeptideRanker software (http: / / distilldeep.ucd.ie / PeptideRanker / ). The toxicity of the identified peptides was predicted using Toxin Pred (https: / / webs.iiitd.edu.in / raghava / toxinpred / index.html). The following tools were used to predict the physicochemical properties of the synthetic peptides; pI and molecular weight were predicted by the Pepdraw tool (https: / / www.tulane.edu / ~biochem / WW / PepDraw / ); average hydrophobicity (GRAVY index) was predicted by the ExPasy tool (https: / / web.expasy.org / protparam / ); HIA was predicted by the AdmetSAR tool (http: / / lmmd.ecust.edu.cn / admetsar3 / index.php); steric hindrance values ​​were predicted by the ToxinPred tool (https: / / webs.iiitd.edu.in / raghava / toxinpred / index.html).

[0099] IC of four synthetic peptides 50 The curves are shown in Figure 4 The IC values ​​of APFFS, FPRPF, FPRPFL and PESFF were determined respectively. 50 The values ​​were 23.12μM, 496.97μM, 1.18μM and 336.63μM. Among these peptides, FPRPFL showed the lowest half-inhibitory concentration. ACE inhibitory activity is significantly affected by amino acids near the C-terminus. The introduction of hydrophobic residues such as phenylalanine (F), tryptophan (W), tyrosine (Y), valine (V), leucine (L) and isoleucine (I) at the C-terminus can enhance the ACE inhibitory activity of the peptide. The characteristics of FPRPFL include a leucine (L) residue at the C-terminus and a proline (P) in the center, which indicates that peptides with similar sequences exhibit strong ACE inhibitory effects.

[0100] Stability of FPRPFL to simulated gastrointestinal digestion: The best performing FPRPFL among the four synthetic peptides was selected to investigate the stability of FPRPFL to simulated gastrointestinal digestion. The synthetic peptide (1 mg / mL) was digested continuously with 0.01% pepsin at pH 2 at 37°C for 3 hours, and then further digested with 0.01% trypsin at pH 7.5 for 3 hours. The enzyme was inactivated by boiling the enzyme for 10 minutes and then centrifuging at 8,000 rpm for 20 minutes.

[0101] ACE inhibitory peptides are hydrolyzed into smaller peptides in the gastrointestinal tract. Therefore, ensuring that the ACE inhibitory peptide is absorbed from the intestine in its intact form can enable it to reach the target site and better exert its antihypertensive effect in vivo. The digestive stability of FPRPFL was evaluated by simulating the enzymatic hydrolysis of FPRPFL in the gastrointestinal tract. Figure 4 (l) As shown in the study, there was no significant difference in the ACE inhibitory activity of FPRPFL before and after simulated gastrointestinal digestion, indicating that FPRPFL is resistant to pepsin and pancreatic digestion. This may be attributed to the presence of proline in FPRPFL, which makes it more stable for gastrointestinal digestion.

[0102] Molecular docking analysis: The 3D structures of ACE (PDB ID: 1O86), AGTR1 (PDB ID: 4YAY), AKT1 (PDB ID: 7NH4), F2 (PDB ID: 1BHX), and REN (PDB ID: 2V0Z) were obtained from the Protein Data Bank (https: / / www.rcsb.org / ). The initial structures were processed using AutoDock Tools 1.5.6 to add hydrogen atoms, assign atom types, and generate pdbqt files for docking. Docking was performed using AutoDock Vina1.2.3. The center coordinates of the docking box were set at the center of gravity of the protein, covering all possible regions of the S1, S2, and S1' pocket domains of the protein. The number of grid points in the XYZ direction was set to Exhaustiveness = 16, and the rest of the parameters use default values ​​to obtain reasonable structures with lower energy.

[0103] Molecular docking methods were used to elucidate the binding mode, location and affinity of ACE to FPRPFL peptide, which demonstrated the in vitro inhibitory effect of FPRPFL on ACE. Table 3 provides the docking energy scores and interaction details between FPRPFL and ACE, including the residues involved. The binding energy between FPRPFL peptide and ACE was calculated by AutoDock4 software to be -8.9 kcal / mol, indicating that this is a spontaneous binding process. The key binding pockets for ACE activity are mainly distributed in the S1, S2 and S1' regions. Figure 5 As shown in (a) to (b), FPRPFL and ACE formed five hydrogen bonds with residues E162, Q281, Y520, and Y523. Specifically, E162 corresponds to S1', Q281 and Y520 are located in S2, and Y523 is located in S1. In addition, a salt bridge with D377 was formed, H387 and R522 participated in ion-π interactions, H410 participated in π-π interactions, and coordinated binding with Zn was observed. Figure 5The e describes the hydrophobic interactions between the peptide and the surrounding amino acids, including A354 and E384 in S1 and K511 and H513 in S2. This binding mode suggests that the peptide effectively occupies the pocket region and binds to S1, S2, and S1' through hydrogen bonds, affecting the functional activity of ACE. Previous studies have shown that non-competitive inhibitory peptides such as PFPGPIPN, TTW, and VHW can occupy the ACE active pocket, which confirms the potent ACE inhibitory activity of FPRPFL.

[0104] Table 3: Molecular docking scoring results

[0105]

[0106] Molecular dynamics simulation: Based on the results of molecular docking analysis, the peptide structure was generated based on the pdb file. All simulations were performed using Gromacs 2023.2. The Amber99SB-ILDN force field parameters were used to parameterize the structures of peptides and proteins and describe their interactions. The simulation system was placed on a The system was placed in a cubic box and hydrated with water molecules from the TIP3P water model. Sodium ions (Na+) were introduced to neutralize the charge of the system. Energy minimization (1,000 kJ / mol / nm) was performed using the steepest descent method, followed by 0.5 ns NVT and 0.5 ns NPT pre-equilibrium simulations. The simulation parameters were set as follows: the temperature was set to 298.15 K, a V-rescale thermostat was used, and the pressure was maintained at 1 bar using a Parrinello-Rahman pressure controller. Long-range van der Waals interactions were The protein was truncated at , dispersion correction was performed using EnerPres, and electrostatic interactions were treated using the particle-mesh Ewald method. Production simulations were performed for 100 ns, with a step size of 2 fs, and trajectories were saved every 5 ps. Trajectory snapshots were obtained using Pymol 2.5.0, and the root mean square deviation (RMSD), root mean square fluctuation (RMSF), protein radius (Gyrate) and the number of hydrogen bonds (Hbonds) of the protein were determined using the integrated tools of Gromacs.

[0107] To further elucidate the influence of stability, flexibility, and binding on the dynamic effects, molecular dynamics simulations of FPRPFL were performed. The docked complex was subjected to 100 ns dynamics simulations. Initially, the RMSD of the peptide, ACE, and the entire complex was calculated ( Figure 6 (a)). The RMSD value of the peptide shows a stable trend from 20 ns, while the protein and complex stabilize after 50 ns, with a value of about It is believed that the value is Fluctuates within a range, indicating that the structure is stable. This indicates that both the system and the binding structure are stable. RMSF analysis ( Figure 6 b) shows low flexibility of amino acids in the binding region, indicating enhanced structural stability by small molecule binding. Gyrate analysis ( Figure 6 c) shows a decrease after 100 ns of simulation, indicating that small molecule binding and enhanced stability lead to a more compact protein structure. Hydrogen bond analysis ( Figure 6 d) showed that there were 4 to 5 hydrogen bonds on average, further confirming the stability of the binding. In addition, FPRPFL interacted with the surrounding pocket amino acids through van der Waals forces, further proving that FPRPFL exerts its antihypertensive effect by tightly binding to ACE.

[0108] Although the present invention has been described above through embodiments, those skilled in the art should understand that without departing from the spirit and substance of the present invention, all improvements and modifications made to the present invention should fall within the protection scope of the present invention.

Claims

1. A highland barley protein-derived antihypertensive peptide, characterized in that: The amino acid sequence of the highland barley protein-derived antihypertensive peptide is one or more of the following sequences: FPRPF, PESFF, APFFS, FPRPFL, PLLFP, EPFLPF, RAPFF, EFFPIG, APFFSL, LPFPQ, The antihypertensive peptide is extracted from highland barley.

2. A method for extracting and identifying antihypertensive peptides from highland barley, characterized in that: The following steps are involved: S1 Database construction: Use public peptide databases to collect non-repetitive experimentally validated antihypertensive peptides; S2 Machine Learning Model Training: Use a machine learning model to predict protein-peptide activity; the machine learning model is GBDT, and the specific data set collected in S1 is used to train the machine learning model. The features used in the feature representation of the machine learning model include PseAAC, and PseAAC uses "Type 2"; S3 Model Evaluation: In the evaluation phase, the model is trained using a five-fold cross-validation method, and five key performance indicators are used to quantitatively evaluate the model's predictive ability, including accuracy, recall, precision, F1 score, and ROC curve; S4 Preparation of defatted highland barley powder and highland barley protein: After grinding highland barley, mixing with an organic solvent, and drying to obtain defatted highland barley powder; the organic solvent is one or more of n-hexane, butane, ethylene glycol, petroleum ether, and ethyl acetate; The defatted highland barley powder is mixed with water, the pH value is adjusted to 10-12, the mixture is heated at 50-70°C and then centrifuged to collect the supernatant; the pH value of the supernatant is adjusted to 4-5, the mixture is centrifuged and the supernatant is discarded; the obtained crude extract is dialyzed, the dialyzate is centrifuged, and the purified highland barley protein is precipitated; S5 preparation of highland barley protein hydrolysate: using one or more of alkaline protease, pepsin, trypsin and papain to hydrolyze highland barley protein, the hydrolysis pH is 2.0 to 8.0, the temperature is 35 to 65° C., and the hydrolysis time is 5 to 8 hours; S6: Determination of angiotensin converting enzyme inhibitory activity: Determine the ACE inhibitory activity of the product obtained in step S5, and select the molecular weight range of the peptide segment with higher ACE inhibitory activity; S7 identified peptide sequences by ultra-performance liquid chromatography-tandem mass spectrometry; Computer prediction of S8 peptide sequences and candidate peptide IC 50 Determination of value: The sequencing results of the peptides in step S7 are applied to the GBDT model to predict ACE inhibitory activity.

3. The method according to claim 2, characterized in that In step S3, The data collected in step S1 is divided into five subsets, four of which are used for training and the remaining one is used for testing; this process is repeated five times, and a different test set is selected in each iteration to ensure that every data point is tested; the model is trained using batch gradient descent, and the optimal settings are determined by grid search optimization.

4. The method according to claim 2, characterized in that: In step S4, highland barley defatted powder and water are mixed in a mass ratio of 1:20-30, and the pH value of the solution is adjusted to 11, and then the mixture is heated at 55-65° C. for 25-35 minutes, and then centrifuged at a speed of 5000-10000 rpm for 10-15 minutes, and the supernatant is collected; the pH value of the liquid is adjusted to 4.5, and the mixture is centrifuged again at a speed of 5000-10000 rpm for 15-30 minutes, the supernatant is discarded, and the precipitate is the crude extract; and this process is repeated 2-4 times.

5. The method according to claim 2, characterized in that: In step S4, the crude extract is mixed with distilled water to form a suspension, and dialyzed for 20 to 30 hours; finally, the dialyzate is centrifuged at a speed of 5000 to 10000 rpm for 10 to 30 minutes to precipitate purified highland barley protein.

6. The method according to claim 2, characterized in that In step S5, HBP is hydrolyzed using papain at a pH of 6 to 7, a temperature of 58 to 62° C., and a hydrolysis time of 5 to 7 hours; and / or The hydrolysis product is further separated: the hydrolysis product is centrifuged with an ultrafiltration centrifuge tube, the hydrolysis product is first filtered through a 10kDa filter membrane, and then the solution obtained by passing through the 10kDa filter membrane is filtered through a 3kDa ultrafiltration membrane to obtain three separate products with different molecular weight ranges.

7. The method according to claim 2, characterized in that In step S7, isolates with a molecular weight range of <3 kDa are selected for peptide sequence identification using ultra-high performance liquid chromatography-tandem mass spectrometry.

8. The method according to claim 2, characterized in that: In step S8, a preliminary screening is first performed: the denovo score, peptide activity ranking and GBDT prediction score are combined to obtain candidate peptides; then a second round of screening is performed: the evaluation index of the second round of screening is to select peptides with a peptide length between 3 and 8 amino acids; the third round of screening: molecular docking is used as the screening procedure, and binding energy is used as a measure of the interaction strength.

9. The method according to claim 8, characterized in that In step S9, candidate peptides were obtained by selecting peptides with a denovo score greater than 90%, a GBDT prediction score greater than 50, and a peptide activity ranking score greater than 0.8; the evaluation index for the second round of screening was to select peptides with a peptide length between 3 and 8 amino acids, and to delete peptide sequences of unknown origin; the third round of screening: peptides with a binding energy ≤-8.0 kcal / mol and a comprehensive score ranking in the top 10 were identified.

10. The method according to any one of claims 2 to 9, characterized in that: The peptides of the sequence predicted in step S8 are artificially synthesized, and the physicochemical properties and half-inhibitory concentration values ​​of the synthesized peptides are tested; preferably, the peptide with the lowest half-inhibitory concentration is selected for synthesis.